OKYO Pharma (OKYO) Capital Expenditures (2026)
OKYO Pharma's (OKYO) quarterly Capital Expenditures came in at -$6.1 billion in Q1 2026.
Powered by 
Analysis
OKYO Pharma (OKYO) Capital Expenditures (2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Capital Expenditures for 1 consecutive years, with -$6.1 billion the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.26 Mn |
| 10 | OKYO Pharma | 1.06 Bn | 1.06 Bn | - | -6.08 Bn |